Eisai News | Markets Insider

TipRanks 6d

UBS Remains a Buy on Eisai Co (ESALF)

TipRanks 10d

Morgan Stanley Sticks to Their Hold Rating for Eisai Co (ESALF)

TipRanks 10d

Eisai Co (ESALF) Gets a Hold from Jefferies

Seeking Alpha 20d

Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen

Seeking Alpha 24d

FDA greenlights first blood test to diagnose Alzheimer's disease

Seeking Alpha 27d

Eisai GAAP EPS of ¥163.76, revenue of ¥789.4B; initiates FY outlook

Seeking Alpha 56d

Biogen/ Eisai win EU approval for Alzheimer’s therapy

Seeking Alpha 67d

Biogen downgraded to Hold at Argus on profit decline expectations

Seeking Alpha 75d

Eli Lilly fails to win EU backing for Alzheimer’s therapy

TipRanks 95d

J.P. Morgan Reaffirms Their Hold Rating on Eisai Co (ESALF)

Seeking Alpha 102d

Biogen, Eisai Alzheimer’s drug sent back for EU nod after safety review

Seeking Alpha 119d

Biogen outlook disappoints amid pressure on multiple sclerosis franchise

Seeking Alpha 119d

Biogen receives Market Perform rating at Bernstein ahead of earnings

Seeking Alpha 124d

Eisai GAAP EPS of ¥160.14, revenue of ¥601.16B; reaffirms FY outlook

Seeking Alpha 131d

Biogen, Eisai Alzheimer’s drug review delayed in EU

Seeking Alpha 134d

FDA approves Leqembi four-week maintenance dosing

Seeking Alpha 138d

Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer

Seeking Alpha 139d

Biogen partner Eisai reportedly sees FY25 launch for home version of Alzheimer’s drug

Seeking Alpha 148d

Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review

TipRanks 154d

Bernstein Keeps Their Buy Rating on Eisai Co (ESALF)

Seeking Alpha 159d

Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds

Seeking Alpha 173d

Bristol in license agreement with BioArctic for two Alzheimer's antibody programs

Seeking Alpha 175d

Eli Lilly Alzheimer's therapy approved in China

TipRanks 181d

Jefferies Remains a Hold on Eisai Co (ESALF)

Seeking Alpha 196d

Anavex gains after seeking EU marketing nod for Alzheimer’s drug

Seeking Alpha 208d

Eisai wins orphan drug status for Lenvima for esophageal cancer

Seeking Alpha 208d

Biogen gains as Eisai wins EU nod for Alzheimer’s drug

Seeking Alpha 214d

Eisai reports HY results

Seeking Alpha 231d

Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use

TipRanks 233d

Bernstein Gives a Buy Rating to Eisai Co (ESALF)

TipRanks 258d

Eisai Co (ESALF) Gets a Hold from Jefferies

Seeking Alpha 260d

Eli Lilly's Alzheimer's therapy approved in Japan

Seeking Alpha 269d

Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer

Seeking Alpha 279d

QIAGEN, Lilly to develop Alzheimer's risk detection test

Seeking Alpha 290d

Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report

Seeking Alpha 292d

Biogen, Eisai new Alzheimer’s drug considered too costly in Britain

Seeking Alpha 293d

Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain

TipRanks 293d

Eisai Co: A Strong Buy on Projected Margin Growth and Market Outperformance

Seeking Alpha 294d

Bristol Myers bid to expand label for liver cancer drug under FDA review

Markets Insider Automation 313d

Eisai earnings: here's what Wall Street expects

Seeking Alpha 314d

Biogen posts Q2 beat as sales from Alzheimer’s drug pick up

Seeking Alpha 314d

Vaccinex stock plunges 24% on mixed results for Alzheimer's study

Seeking Alpha 315d

Novo’s older obesity drug benefits Alzheimer’s patients in small trial

TipRanks 317d

Japanese Stocks: Eisai Shares Plummet as EU Rejects Alzheimer’s Drug

Seeking Alpha 319d

AbbVie exits Alzheimer’s program on lack of differentiation

Seeking Alpha 320d

Biogen-partnered Alzheimer’s therapy fails to clear EU hurdle

TipRanks 324d

Jefferies Reaffirms Their Hold Rating on Eisai Co (ESALF)

TipRanks 331d

Analysts Offer Insights on Healthcare Companies: Eisai Co (OtherESALF) and Amgen (AMGN)

Benzinga 342d

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst

Seeking Alpha 343d

Eli Lilly wins FDA approval of donanemab for Alzheimer's

News for Eisai Co. Ltd.